Key points
- CDC's Advanced Molecular Detection (AMD) program is helping build and integrate the use of genomic sequencing technologies into public health nationwide.
- The cumulative local investment to Minnesota from FY2021-2023 is $20,227,757.
- Minnesota serves the Central region as the Bioinformatic Regional Resource Lead, AMD Training Lead, and Community of Practice Domain Lead.
- Minnesota is the principal investigator for the Minnesota Pathogen Genomics Center of Excellence.
- The University of Minnesota received a research award to advance pathogen genomics for public health.
![Minnesota map of blue dots on white background Minnesota map of colored dots on white background](/advanced-molecular-detection/images/investments/investment-mn-dots.jpg)
Total Investment: $20,227,757
- State and Local Investment: $12,098,884
- Research Awards: $928,873
- Centers of Excellence (FY22-23): $7,200,000
Funding to public health departments includes support from the American Rescue Plan of 2021 and AMD annual appropriations in FY2021-2023.
Implementing AMD technology
The AMD program builds and integrates laboratory, bioinformatics, and epidemiology technologies across CDC and nationwide. Since 2014, AMD has received support from Congress—now a $40 million per year appropriation—to implement these technologies in public health programs. Through investments in AMD technologies, CDC is improving both public health outcomes and preparedness in dozens of areas including foodborne disease, influenza, antibiotic resistance, hepatitis, pneumonia, and meningitis.
With funding from the American Rescue Plan Act of 2021, the AMD program developed a multi-year plan to expand support to state, local, and territorial public health laboratories providing more staff and resources to collect and sequence SARS-CoV-2 specimens, identify and track variants, and share data for public health use.
Workforce development
Minnesota is part of the Central region. In 2018, the AMD program established seven workforce development regions across the country. Each region has an AMD training lead and a bioinformatics lead. This provides a network of customized AMD support which helps develop skills and provides training assistance to public health labs across the country
Minnesota's Bioinformatic Regional Resource Lead acts as a regional consultant. They provide support to labs within the region on data analysis and how to interface with IT departments. Its AMD Training Lead provides support to labs in the Central region on pathogen-specific training and cross-cutting AMD training to help staff develop the critical skills necessary to extract, analyze, and interpret sequencing data.
AMD Platform Community of Practice (CoP)
The Office of AMD has established five communities of practice to build processes and tools for relevant interests, concerns, and priorities regarding the AMD Platform. The AMD Platform will serve CDC programs and STLT partners by providing a common infrastructure to perform genomic epidemiology and contribute high-quality data to publicly available data repositories. Minnesota's Domain Leader facilitates collaboration between OAMD and the public health community for the Applied Genomic Epidemiology CoP.
US Pathogen Genomics Centers of Excellence (PGCoE) network
The US Pathogen Genomics Centers of Excellence (PGCoE) network will foster and improve innovation and technical capacity in the use of pathogen genomics, molecular epidemiology, and bioinformatics in the field of public health. The Minnesota Pathogen Genomics Center of Excellence is led by the Minnesota Department of Health with primary partners the University of Minnesota and the Mayo Clinic. They will also be partnering with the University of Pennsylvania College of Veterinary Medicine.
University and research partners in Minnesota
These awards are intended to fill knowledge gaps and promote innovation in the U.S. response to the COVID-19 pandemic. Funding awards are determined through a competitive selection process based on scientific needs and available funds.
Awards to university and research partners were funded through appropriations supporting the COVID-19 response.